Garrett W. Cooper

Garrett W. Cooper

Auto-generated profile, based on publicly available information

Garrett W. Cooper

Genetics and Molecular Biology Graduate Program, Emory University School of Medicine, Atlanta, Georgia

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 July 2022 in Cancers
Verified
Journal Article
Open access
PDF file
GCGarrett W. Cooper
Garrett W. Cooper
AHAndrew Hong
Andrew Hong
SMARCB1 is a critical component of the BAF complex that is responsible for global chromatin remodeling. Loss of SMARCB1 has been implicated in the initiation of cancers such as malignant rhabdoid tumor (MRT), atypical teratoid rhabdoid tumor (ATRT), and, more recently, renal medullary carcinoma (RMC). These SMARCB1-deficient tumors have remarkably stable genomes, offering unique insights into the epigenetic mechanisms in cancer biology. Given the lack of druggable targets and the high mortality associated with SMARCB1-deficient tumors, a significant research effort has been directed toward understanding the mechanisms of tumor transformation and proliferation. Accumulating evidence suggests that tumorigenicity arises from aberrant enhancer and promoter regulation followed by dysfunctional transcriptional control. In this review, we outline key mechanisms by which loss of SMARCB1 may lead to tumor formation and cover how these mechanisms have been used for the design of targeted therapy.

6 December 2022 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
RJRobert B. Jones
Robert B. Jones
JFJonathan Farhi
Jonathan Farhi
MAMiranda Adams
Miranda Adams
KPKiran K. Parwani
Kiran K. Parwani
GCGarrett W. Cooper
Garrett W. Cooper
JSJennifer M Spangle
Jennifer M Spangle
The high frequency of aberrant PI3K pathway activation in hormone receptor–positive (HR+) breast cancer has led to the development, clinical testing, and approval of the p110α-selective PI3K inhibitor alpelisib. The limited clinical efficacy of alpelisib and other PI3K inhibitors is partially attributed to the functional antagonism between PI3K and estrogen receptor (ER) signaling, which is mitigated via combined PI3K inhibition and endocrine therapy. We and others have previously demonstrated chromatin-associated mechanisms by which PI3K supports cancer development and antagonizes ER signaling through the modulation of the H3K4 methylation axis, inhibition of KDM5A promoter H3K4 demethylation and KMT2D/MLL4-directed enhancer H3K4 methylation. Here we show that inhibition of the H3K4 histone methyltransferase MLL1 in combination with PI3K inhibition impairs HR+ breast cancer clonogenicity and cell proliferation. While combined PI3K/MLL1 inhibition reduces PI3K/AKT signaling and H3K4 methylation, MLL1 inhibition increases PI3K/AKT signaling through the dysregulation of gene expression associated with AKT activation. These data reveal a feedback loop between MLL1 and AKT whereby MLL1 inhibition reactivates AKT. We show that combined PI3K and MLL1 inhibition synergizes to cause cell death in in vitro and in vivo models of HR+ breast cancer, which is enhanced by the additional genetic ablation of the H3K4 methyltransferase and AKT target KMT2D/MLL4. Together, our data provide evidence of a feedback mechanism connecting histone methylation with AKT and may support the preclinical development and testing of pan-MLL inhibitors.Significance: Here the authors leverage PI3K/AKT-driven chromatin modification to identify histone methyltransferases as a therapeutic target. Dual PI3K and MLL inhibition synergize to reduce clonogenicity and cell proliferation, and promote in vivo tumor regression. These findings suggest patients with PIK3CA-mutant, HR+ breast cancer may derive clinical benefit from combined PI3K/MLL inhibition.

4 April 2023
Verified
Other
Open access
RJRobert B. Jones
Robert B. Jones
JFJonathan Farhi
Jonathan Farhi
MAMiranda Adams
Miranda Adams
KPKiran K. Parwani
Kiran K. Parwani
GCGarrett W. Cooper
Garrett W. Cooper
JSJennifer M Spangle
Jennifer M Spangle
The high frequency of aberrant PI3K pathway activation in hormone receptor–positive (HR+) breast cancer has led to the development, clinical testing, and approval of the p110α-selective PI3K inhibitor alpelisib. The limited clinical efficacy of alpelisib and other PI3K inhibitors is partially attributed to the functional antagonism between PI3K and estrogen receptor (ER) signaling, which is mitigated via combined PI3K inhibition and endocrine therapy. We and others have previously demonstrated chromatin-associated mechanisms by which PI3K supports cancer development and antagonizes ER signaling through the modulation of the H3K4 methylation axis, inhibition of KDM5A promoter H3K4 demethylation and KMT2D/MLL4-directed enhancer H3K4 methylation. Here we show that inhibition of the H3K4 histone methyltransferase MLL1 in combination with PI3K inhibition impairs HR+ breast cancer clonogenicity and cell proliferation. While combined PI3K/MLL1 inhibition reduces PI3K/AKT signaling and H3K4 methylation, MLL1 inhibition increases PI3K/AKT signaling through the dysregulation of gene expression associated with AKT activation. These data reveal a feedback loop between MLL1 and AKT whereby MLL1 inhibition reactivates AKT. We show that combined PI3K and MLL1 inhibition synergizes to cause cell death in in vitro and in vivo models of HR+ breast cancer, which is enhanced by the additional genetic ablation of the H3K4 methyltransferase and AKT target KMT2D/MLL4. Together, our data provide evidence of a feedback mechanism connecting histone methylation with AKT and may support the preclinical development and testing of pan-MLL inhibitors.Significance:Here the authors leverage PI3K/AKT-driven chromatin modification to identify histone methyltransferases as a therapeutic target. Dual PI3K and MLL inhibition synergize to reduce clonogenicity and cell proliferation, and promote in vivo tumor regression. These findings suggest patients with PIK3CA-mutant, HR+ breast cancer may derive clinical benefit from combined PI3K/MLL inhibition.

4 April 2023
Verified
Other
Open access
RJRobert B. Jones
Robert B. Jones
JFJonathan Farhi
Jonathan Farhi
MAMiranda Adams
Miranda Adams
KPKiran K. Parwani
Kiran K. Parwani
GCGarrett W. Cooper
Garrett W. Cooper
JSJennifer M Spangle
Jennifer M Spangle
Figure S4 shows combined PI3K and MLL1 inhibition reduces cell viability and enhances apoptosis

4 April 2023
Verified
Other
Open access
RJRobert B. Jones
Robert B. Jones
JFJonathan Farhi
Jonathan Farhi
MAMiranda Adams
Miranda Adams
KPKiran K. Parwani
Kiran K. Parwani
GCGarrett W. Cooper
Garrett W. Cooper
JSJennifer M Spangle
Jennifer M Spangle
Figure S3 shows additional transcriptional and genomics analyses that support MLL1 inhibitor-driven hyperactivation of AKT

4 April 2023
Verified
Other
Open access
RJRobert B. Jones
Robert B. Jones
JFJonathan Farhi
Jonathan Farhi
MAMiranda Adams
Miranda Adams
KPKiran K. Parwani
Kiran K. Parwani
GCGarrett W. Cooper
Garrett W. Cooper
JSJennifer M Spangle
Jennifer M Spangle
Figure S3 shows additional transcriptional and genomics analyses that support MLL1 inhibitor-driven hyperactivation of AKT